TAFA chemokine like family member 5Genealiases: FAM19A5 · QLLK5208 · TAFA-5 · UNQ5208
Q-omics provides the consensus-scored TAFA5 profile across patient tissues and cancer cell-line models. TAFA5 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TAFA5 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, TAFA5 RNA expression shows 18,469 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, COAD, and GBM as cancer lineages where TAFA5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAFA5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAFA5 survival associations across molecular data types. TAFA5 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAFA5 RNA expression–survival associations across cancer types. High TAFA5 expression shows unfavorable associations in ACC, UVM and KIRP, but favorable associations in LGG, KIRC and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TAFA5 RNA expression.
This table summarizes TAFA5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TAFA5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAFA5 shows lower tumor expression in KICH and higher tumor expression in COAD, KIRC, THCA, BRCA and CHOL. The COAD box plot shows higher TAFA5 RNA expression in tumor versus normal tissue (log2 FC = +1.254, t-test p < 0.001).
This table shows molecular features associated with TAFA5 in patient tissues and cancer cell lines. In patient samples, TAFA5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TAFA5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
